Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.13 is in line with its 3-year average of -1.04, around the middle of its 3-year range (-2.09–0.40).
15.99% above its 12-month average of -1.34.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.21.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 12 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.13
EARNINGS PER SHARE (EPS) AVG TTM
-1.34
EARNINGS PER SHARE (EPS) AVG 3Y
-1.04
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+15.99%
CURRENT VS 3Y AVG
-8.39%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Zura Bio Limited
Market Cap
$376.19M
Earnings Per Share (EPS)
-1.13
TTM Avg
-1.34
3Y Avg
-1.04
5Y Avg
N/A
Market Cap
$376.01M
Earnings Per Share (EPS)
-0.50
TTM Avg
-5.17
3Y Avg
-17.19
5Y Avg
-12.52
Market Cap
$374.50M
Earnings Per Share (EPS)
-2.94
TTM Avg
-3.49
3Y Avg
-2.70
5Y Avg
-2.28
Market Cap
$380.37M
Earnings Per Share (EPS)
-1.54
TTM Avg
-2.79
3Y Avg
-2.67
5Y Avg
-2.08
Market Cap
$369.50M
Earnings Per Share (EPS)
-3.33
TTM Avg
-2.70
3Y Avg
-1.54
5Y Avg
-2.91
Market Cap
$385.15M
Earnings Per Share (EPS)
-3.79
TTM Avg
-4.17
3Y Avg
-5.22
5Y Avg
-3.47
Market Cap
$361.64M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.30
3Y Avg
-1.38
5Y Avg
-1.95
Market Cap
$359.53M
Earnings Per Share (EPS)
-0.14
TTM Avg
-0.19
3Y Avg
-0.48
5Y Avg
-0.56
Market Cap
$396.93M
Earnings Per Share (EPS)
-1.71
TTM Avg
-1.36
3Y Avg
-1.12
5Y Avg
-1.12
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zura Bio Limited (ZURA) | $376.19M | -1.13 | -1.34 | -1.04 | N/A |
| Canopy Growth Corporation (CGC)vs › | $376.01M | -0.50 | -5.17 | -17.19 | -12.52 |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $374.50M | -2.94 | -3.49 | -2.70 | -2.28 |
| Orthofix Medical Inc. (OFIX)vs › | $380.37M | -1.54 | -2.79 | -2.67 | -2.08 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | -3.33 | -2.70 | -1.54 | -2.91 |
| REGENXBIO Inc. (RGNX)vs › | $385.15M | -3.79 | -4.17 | -5.22 | -3.47 |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | -1.30 | -1.38 | -1.95 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | -0.14 | -0.19 | -0.48 | -0.56 |
| Shoulder Innovations, Inc. (SI)vs › | $396.93M | -1.71 | -1.36 | -1.12 | -1.12 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | -3.31 | -3.43 | -2.65 | -2.61 |
Trailing EPS (TTM)
$-1.13
Forward EPS (Est.)
$-0.82
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2024-12-31 | -0.60 |
| 2023-12-31 | -2.09 |
| 2022-12-31 | -1.88 |
| 2021-12-31 | 0.40 |
